NEW YORK, Feb. 13, 2018 -- TransPerfect Life Sciences, a leading provider of services and technologies to support clinical trials and product development for the biopharmaceutical industry, today announced the release of myTI, the company’s ground-breaking mobile application that enables real-time eTMF access and functionality for study teams on the go.
myTI is a mobile extension of Trial Interactive, TransPerfect’s award-winning cloud-based e-clinical technology designed by clinical professionals for clinical professionals to simplify management of product development, from study start up to commercialization. myTI offers significant benefits to Trial Interactive users by placing key eTMF functionality at the fingertips of study teams no matter where they are. By taking these study processes mobile, including secure document capture, query resolution, and task management, myTI enables users to maximize TMF health and keep studies moving at all times.
Highlights of myTI include:
- Document Detection, Capture, and Submission: Securely capture and upload documents using your mobile device camera and a simple auto-capture interface that straightens and adjusts documents prior to PDF conversion and upload
- Query Resolution: Review documents with queries and resolve them within the mobile interface
- Document Status: View status, metadata, and update/re-submit expired documents from your phone or tablet
- Geolocation: Auto-populate site information based on document capture location
- Role Specific Access: Customized access levels can be set for CRAs, project managers, TMF leads, and other stakeholders.
- iPhone and iPad iOS: Versions 10.3+ with support back to model 5. Android version to release in Q2 2018
- Secure Touch ID® and Face ID® login: Secure and configurable for devices that support TouchID® or Face ID®
- CFR 21 Part 11 Compliant: Complies with regulatory standards for hosting eTMF documents
“By enabling a move away from archaic paper TMF management, mobile document capture and upload at investigative sites is a huge step forward in product development and for simplifying the significant project management and CRA challenges involved with bringing treatments to market,” said Michael Smyth, General Manager of TransPerfect Life Sciences Solutions. “myTI will equip study teams with on-the-go access to eTMF materials, which will cut lengthy upload timelines and allow filing with near real time availability, helping to expedite overall timelines and ensuring TMF inspection readiness.”
Demos for Trial Interactive myTI can be scheduled by emailing [email protected].
About Trial Interactive
TransPerfect’s Trial Interactive solution provides a collaborative, web-based platform for clinical development that enables sponsors, CROs, IRBs, and other vendors to maintain and update clinical trial documentation in a secure online environment, adhering to global regulatory requirements. With fully searchable solutions including investigator portals, Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of TransPerfect’s Life Sciences division, Trial Interactive is dedicated to working with clients on a global, collaborative level, supporting a wide range of requirements including e-feasibility, study start-up, eTMF review/reconciliation, mobile applications, learning management and document management systems, investigator portals, pharmacovigilance and safety management, and endpoint adjudication. For more information on Trial Interactive, please contact [email protected] or +1 212.400.8848, or visit www.trialinteractive.com.
About TransPerfect
TransPerfect is the world’s leading provider of language services and technology solutions for global business. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.
Contact:
Ryan Simper +1 212.689.5555
[email protected]


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



